Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term RISK. Found 23 abstracts

no pagination
Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment: current standards and future directions. Current Opinion in Oncology. 2014 May;26(3):252-8.   PMCID: No NIH funding
Miller SM, Roussi P, Scarpato J, Wen KY, Zhu F, Roy G. Randomized trial of print messaging: the role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men. Psycho-Oncology. 2014 Apr;23(4):404-11.   PMCID: PMC4091779
Huo DZ, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. Journal of Clinical Oncology. 2009 Mar;27(8):1184-90.   PMCID: PMC2667822
Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, Iriondo-Perez J, Miron A, Santella RM, Whittemore A, Andrulis IL, Buys SS, Daly MB, Hopper JL, Seminara D, Senie RT, Terry MB, Breast Canc Family Registry; Breast Canc Family R. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Research and Treatment. 2009 Jul;116(2):379-86.   PMCID: PMC2775077
Weitzner B, Meehan T, Xu QF, Dunbrack RL. An unusually small dimer interface is observed in all available crystal structures of cytosolic sulfotransferases. Proteins-Structure Function and Bioinformatics. 2009 May;75(2):289-95.   PMCID: PMC 2728805
Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer. Journal of Clinical Oncology. 2009 Jan;27(1):100-5.   PMCID: PMC 2645095
Williams SG, Buyyounouski MK, Pickles T, Kestin L, Martinez A, Hanlon AL, Duchesne GM. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. International Journal of Radiation Oncology Biology Physics. 2008 Mar;70(4):1169-75.
Apicella C, Dowty JG, Dite GS, Jenkins MA, Senle RT, Daly MB, Andrulis IL, John EM, Buys SS, Li FP, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, Southey MC, Foulkes WD, Hopper JL. Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clinical genetics. 2007 Aug;72(2):87-97.
Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. International journal of cancer. 2007 Dec;121(12):2661-7.
Deshpande N, Weinberg DS. The evolving role of CT colonography. Cancer Investigation. 2007 Jan;25(2):127-33.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Nov;107(2):260-5.
Jordan VC. Successful translation research with selective oestrogen receptor modulators to treat and prevent breast cancer. Geburtshilfe Und Frauenheilkunde. 2007 May;67(5):443-50.
Pakkanen S, Baffoe-Bonnie AB, Matikainen MP, Koivisto PA, Tammela TL, Deshmukh S, Ou L, Bailey-Wilson JE, Schleutker J. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Human Genetics. 2007 Apr;121(2):257-67.
Rebbeck TR, Troxel AB, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Norman S, Bunin G, DeMichele A, Berlin M, Schinnar R, Berlin JA, Strom BL. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiology Biomarkers & Prevention. 2007 Mar;16(3):444-50.
Roach M, De Silvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, Fisher B, Hanks G, Shipley WU, Pollack A, Sandler H, Watkins-Bruner D. Racial differences in cyp3a4 genotype and survival among men treated on radiation therapy oncology group (rtog) 9202: A phase III randomized trial. International Journal of Radiation Oncology Biology Physics. 2007 Sep;69(1):79-87.
Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A. Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detection and Prevention. 2007 Jan;31(1):50-8.
Tchou J, Ward MR, Volpe P, Palma MD, Medina CA, Sargen M, Sonnad SS, Godwin AK, Daly M, Winchester DJ, Garber J, Weber BL, Domchek S, Nathanson KL. Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Clinical Breast Cancer. 2007 Jun;7(8):627-33.
Yu ZW, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of akt (Ser(473)) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiology Biomarkers & Prevention. 2007 Mar;16(3):553-8.
Jordan VC. Optimising endocrine approaches for the chemoprevention of breast cancer - Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial. European Journal of Cancer. 2006 Nov;42(17):2909-13.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term RISK

RISK WOMEN POSTMENOPAUSAL WOMEN THERAPY breast cancer RADICAL PROSTATECTOMY PREVALENCE OVARIAN-CANCER GENE prostate cancer ANTIESTROGENS RECURRENCE radiotherapy MORTALITY ASSOCIATION Oncology RADIOTHERAPY BREAST-CANCER UNITED-STATES GERMLINE MUTATIONS TRIAL POPULATION PROSTATE-CANCER RANDOMIZED-TRIAL SUSCEPTIBILITY GENES AA fibroblast growth factor on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY mutations human glandular kallikrein 2 PROTEIN-KINASE prevention tamoxifen partner IMMEDIATE HEREDITARY ashkenazi jewish mutation ACTIVATION BOWEL PROJECT P-1 INTERDEPENDENCE BRCA2 biochemical failure GENETIC VARIANT PREVENTION PSA measurements) and cancer-specific survival (CSS) FAILURE prognostic models CONVENTIONAL COLONOSCOPY OVEREXPRESSION communication messages ANTIGEN PERCEPTIONS SERM CARRIER PROBABILITIES FHA DOMAIN BMI DELETIONS body weight SCREEN CARBOPLATIN DISEASE Psychology MUTATION ANALYSIS PHASE-III HYDROXYSTEROID SULFOTRANSFERASE (T2c-4 and PSA level < 150 ng DEATH PHYSICAL-ACTIVITY FAMILY-HISTORY (P-Cox = 04) The significant posttreatment PSADTs were also CARRIERS BRCA1 STAR mutation ovarian cancer significant predictors of CSS (P-Cox < 0001) After adjusting for T GERMLINE FIBROBLAST-GROWTH-FACTOR 185DELAG RALOXIFENE (Methods and Materials: ) under bar We analyzed posttreatment PSA COMPETING susceptibility cHEK2-breast-cancer-mutation or in combination with 24 65-70 Gy of radiation therapy (n = 761) C-MET CANCER-SUSCEPTIBILITY GENES predictive markers genetic polymorphisms BRCA1 MUTATIONS randomized treatment was a significant predictor for CSS (p(Cox) = months of adjuvant androgen deprivation (n = 753) Using an adjusted PTEN TAMOXIFEN HAPLOTYPES men were randomized to neoadjuvant androgen deprivation and April 1995 POPULATION STRATIFICATION MOLECULE Biomedical smoking ADJUVANT TREATMENT INTERVENTIONS RESIDUAL CANCER MUTATIONS CYTOCHROME P4501B1 COOPERATIVE-ONCOLOGY-GROUP OBESITY PROTEIN EXPRESSION the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint OUTCOMES PROTEINS BEHAVIOR basic TRUNCATING BRCA1 but did not meet all of Prentice's significantly associated with CSS SEQUENCE VARIANTS LONG PELVIC LYMPHADENECTOMY HUMAN-PAPILLOMAVIRUS OVERWEIGHT NONCARRIERS the randomized treatment GENETIC POLYMORPHISMS PURIFICATION POLYMORPHISMS FAMILIES CLINICAL UTILITY ESTROGEN SULFOTRANSFERASE PROGNOSTIC MODELS PACLITAXEL SELF-EXAMINATION INDIVIDUALS SURGICAL ADJUVANT BREAST chemotherapy RISK AB (Purpose:) under bar We evaluated whether posttreatment head and neck squamous cell cancer EXTRACOLONIC FINDINGS ovarian ENDOMETRIAL CANCER SUSCEPTIBILITY GENE JEWS Gleason score and PSA stage-all of Prentice's requirements were not TYROSINE KINASE monitoring style Ashkenazi Jewish men SUSCEPTIBILITY indicating that the effect of PSADT on CSS was not independent of met
Last updated on Monday, November 04, 2019